Breast Cancer Foundation NZ
Targeting growth hormone signal transduction in breast cancer
April 2017
Research Grant
What is the problem and who is affected?
The use of humanised monoclonal antibodies to inhibit growth factors essential to tumour growth has proved a very successful treatment. However, not all patients will respond to this treatment - a variety are needed to ensure that the most people possible are able to receive effective treatment.
What is this research hoping to achieve?
Human growth hormone expression in breast cancer has been associated with reduced survival in patients. Dr Perry is going to investigate whether a monoclonal antibody could be developed to target this hormone (rather than just the growth factors), reducing likelihood of recurrence.
Funding was provided by a tripartite partnership with BCFNZ, the Health Research Council of New Zealand (HRC) and Breast Cancer Cure (BCC).
-
JuneResearch Grant
Helping surgeons accurately locate breast tumours
-
JuneResearch Grant
New sugar-based drug to stop breast cancer spreading
-
JuneResearch Grant
A personalized vaccine for breast cancer
-
JuneResearch Grant
A simpler way to check for the spread of breast cancer
-
JuneResearch Grant
A new way to treat breast cancers
-
AprilResearch Grant
Development of inhibitors as anti-cancer therapeutics
-
AprilResearch Grant
The potential of immunotherapy as a treatment for ER+ breast cancer
-
AprilResearch Grant
Targeting growth hormone signal transduction in breast cancer
-
MarchResearch Grant
Five-year research partnership targets breast cancer vaccine
-
FebruaryBelinda Scott Fellowship
Benefits of an integrated tai chi programme in breast cancer